Androgen receptor plasticity and its implications for prostate cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer (PCa) is a leading cause of cancer mortality in men.
• Androgen receptor (AR) signaling is a key target in PCa therapy, with drugs like enzalutamide showing initial success.
• Acquired resistance to AR-targeted therapies is a major clinical challenge, limiting long-term treatment efficacy.

Purpose of the Study:

• To investigate the mechanisms of acquired resistance to AR-targeted therapies in prostate cancer.
• To characterize specific AR mutations that confer resistance and alter drug response.
• To highlight the clinical implications of AR mutations in PCa treatment and the need for improved diagnostics and therapeutics.

Main Methods:

• Analysis of AR signaling pathways in resistant prostate cancer models.
• Identification and functional characterization of AR point mutations in the ligand-binding domain.
• Assessment of drug response in cell lines and patient samples harboring specific AR mutations.

Main Results:

• Gain-of-function point mutations in the AR ligand-binding domain were identified as a critical mechanism of resistance.
• These mutations can convert anti-androgen drugs, such as enzalutamide, into potent AR agonists.
• AR splice variants and overexpression also contribute to treatment resistance.

Conclusions:

• AR mutations represent a significant challenge for current prostate cancer therapies.
• Understanding these resistance mechanisms is crucial for developing novel treatment strategies and patient screening protocols.
• Further research is needed to overcome AR-mediated resistance and explore similar mechanisms in other hormone-driven cancers.